Citizens Jmp Reiterates Market Outperform Rating for CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “market outperform” rating reissued by equities researchers at Citizens Jmp in a report issued on Monday,Benzinga reports. They currently have a $80.00 target price on the stock. Citizens Jmp’s price target suggests a potential upside of 38.60% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on CRSP. UBS Group set a $80.00 price objective on shares of CRISPR Therapeutics in a report on Friday, June 12th. Sanford C. Bernstein boosted their target price on CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $68.06.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $57.72 on Monday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. CRISPR Therapeutics has a 1 year low of $44.12 and a 1 year high of $78.48. The firm has a fifty day moving average of $53.62 and a 200-day moving average of $52.73. The company has a market cap of $5.58 billion, a price-to-earnings ratio of -12.13 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The business had revenue of $10.18 million for the quarter. As a group, equities analysts anticipate that CRISPR Therapeutics will post -4.47 earnings per share for the current year.

Hedge Funds Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its holdings in CRISPR Therapeutics by 175.1% during the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after buying an additional 296 shares in the last quarter. Mcguire Capital Advisors Inc. bought a new stake in CRISPR Therapeutics during the 4th quarter worth about $25,000. Ramirez Asset Management Inc. acquired a new position in CRISPR Therapeutics during the 4th quarter valued at about $26,000. Rothschild Investment LLC boosted its stake in shares of CRISPR Therapeutics by 836.7% in the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after purchasing an additional 502 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in shares of CRISPR Therapeutics in the 4th quarter valued at about $37,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.